Cancer Medicine 2.0: Vision Zero Initiative Pushes for Earlier Intervention

The "Redefining Oncology" summit in Berlin brought together experts from research, science, medicine, patient advocacy, and the pharmaceutical industry to discuss advancements in cancer care and prevention. The Vision Zero initiative, active for nearly a decade, aims to eliminate all preventable cancer cases.

The summit's central theme was the "redefinition" of oncology, emphasizing the need for earlier intervention in diagnosis and treatment. Professor Christof von Kalle highlighted that cancer care often suffers from delayed diagnoses and insufficient preventative focus, situations not tolerated in sectors like aviation or occupational safety. He stressed that modern approaches, including molecular diagnostics, immunotherapies, and artificial intelligence (AI), offer significant opportunities to prevent a large proportion of current cancer deaths.

Discussions also focused on the importance of research funding and pharmaceutical innovation. Dr. Daniel Steiners from Roche emphasized that the regulatory and legislative environment for research directly impacts the availability of new medicines and industry competitiveness. He noted that Europe lags behind countries like the US and China in research speed and efficiency, partly due to excessive bureaucracy and lack of digitalization.

Steiners called for a more innovation-friendly environment and reliable reimbursement conditions. "Research and innovation are not a cost," he stated, "but growth, industry, and future policy." He believes Germany has the potential to become the world's "pharmacy" while strengthening its economic position.

The summit aimed to accelerate cancer prevention, diagnosis, and treatment through scientific progress and improved care pathways. Experts underscored the necessity of reducing bureaucracy and fostering an innovation-friendly atmosphere to ensure cancer patients receive the best possible care more quickly.